Dynogen Drug Enters Trial for Treatment of Chronic Vomiting
Posted on: Thursday, 16 March 2006, 21:00 CST
Dynogen Pharmaceuticals has dosed its first participants in a phase II trial of DDP225 in patients with chronic functional vomiting.
Chronic functional vomiting (CFV) is believed to be caused by the abnormal function of the muscles or nerves controlling the organs of the middle and upper gastrointestinal tract. In this placebo controlled trial, multiple symptom-based endpoints will be assessed.
Chronic functional vomiting is the second clinical indication for DDP225, an orally-active compound that targets two key pathways that control the gastrointestinal system. The company initiated a phase II trial for the drug in patients with diarrhea-predominant irritable bowel syndrome (IBS-d) in October 2005.
"DDP225 represents a novel and potentially the first treatment option for patients suffering from CFV. This unique study is designed to both validate efficacy and lay the pathway for a rapid product registration trial," said Dr Lee Brettman, CEO at Dynogen.
DDP225 is both a noradrenaline reuptake inhibitor and a specific serotonin receptor antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system.
The unique combination of noradrenaline reuptake inhibition and serotonin antagonism in one orally delivered compound represents a novel approach to treating IBS-d and similar diseases. Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003.
Source: Datamonitor
Related Articles
- Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial
- Data From Clinical Trial of EndoBarrier(TM) Gastrointestinal Liner in Patients With Type 2 Diabetes to Be Presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York City
- Studies Confirm Balloon Sinuplasty(TM) Helps Chronic Sinusitis Patients
- Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
- Transgene Initiates A Phase I Trial of Its Therapeutic Vaccine Candidate TG4040 for Patients Chronically Infected With the Hepatitis C Virus
- Neurogen Commences Phase II Clinical Trial in Chronic Insomnia Patients
- Healthcare Compliance Services Company Reaches Agreement With ALR Technologies to Provide the ALRT500 Disease Management Compliance Reminder and Monitoring System to Selected Chronic Care Patient Population
- Presence of TT Virus Infection in Chronic Hepatitis Patients From a Hospital in New Delhi, India
- Geron Announces FDA Clearance to Start Clinical Trials of Its Telomerase Inhibitor Drug GRN163L in Patients With Chronic Lymphocytic Leukemia
- Raven Biotechnologies Initiates Phase 1/2a Trial of RAV12 in Gastrointestinal Cancers
 |
 |
User Comments (0)
RSS Feeds